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Germline and somatic PTEN mutations are found in Cowden syndrome (CS) and multiple sporadic malignan-
cies, respectively. PTEN function appears to be modulated by subcellular compartmentalization, and mislo-
calization may affect function. We have shown that cellular ATP levels affect nuclear PTEN levels. Here, we
examined the ATP-binding capabilities of PTEN and functional consequences, relevant to cancer-associated
mutations. PTEN mutation analysis of CS patients and sporadic colorectal carcinomas and comparative ami-
noacid analysis were utilized to identify mutations in ATP-binding motifs. The ability of wild-type (WT) or
mutant PTEN to bind ATP was assessed by ATP–agarose-binding assays. Subcellular fractionation, western
blotting, confocal microscopy and growth assays were used to determine relative nuclear-cytoplasmic local-
ization and function. Somatic colorectal carcinoma-derived PTEN missense mutations were associated with
nuclear mislocalization. These mutations altered cellular proliferation, apoptosis and anchorage-dependent
growth. Examination of PTEN’s amino acid sequence revealed these mutations resided in previously unde-
scribed ATP-binding motifs (c.60–73; c.122–136). In contrast to WT PTEN, both cancer-associated somatic
and germline-derived PTEN missense mutations, which lie within the ATP-binding motifs, result in mutant
PTEN that does not bind ATP efﬁciently. We also show that CS patients with germline ATP-binding motif-
mutations had nuclear PTEN mislocalization. Of four unrelated patients with functional germline ATP-binding
domain mutations, all three female patients had breast cancers. Germline and somatic mutations within
PTEN’s ATP-binding domain play important pathogenic roles in both heritable and sporadic carcinogenesis
by PTEN nuclear mislocalization resulting in altered signaling and growth. Manipulation of ATP may rep-
resent novel therapies in tumors with such PTEN alterations.
INTRODUCTION
Germline mutations in PTEN (phosphatase and tensin
homolog deleted on chromosome 10; MIM# 601728), encod-
ing a lipid and protein phosphatase that mediates cell cycle
arrest and apoptosis, were ﬁrst described in Cowden syndrome
[CS; MIM# 158350] (1). Germline PTEN mutations have been
identiﬁed in 85% of CS probands, who carry an up to 50% risk
of female breast cancer and 10% risk of epithelial thyroid
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disorder Bannayan–Riley–Ruvalcaba syndrome and variable
frequencies of individuals with several other related syn-
dromes were also shown to carry germline PTEN mutations
(2). Similarly, somatic mutations or deletions of PTEN have
been identiﬁed in a broad range of sporadic tumor types (2).
Initial reports suggested that PTEN localized exclusively to
the cytoplasm (3,4). However, it is now well established that a
signiﬁcant pool of PTEN protein is localized to, and functional
within, the nucleus (4–8). Decreased nuclear (wild-type, WT)
PTEN (WTPTEN) has been associated with more aggressive
disease in patients with colorectal cancer (9,10), cutaneous
melanoma (11,12), esophageal squamous cell carcinoma
(13), pancreatic islet cell tumors (14) and cases of large B
cell lymphoma (15). Nuclear PTEN appears to play a role in
cell cycle regulation, MAPK phosphorylation and modulating
cyclin D1 levels in various cell types (7,16–18). Furthermore,
nuclear PTEN is involved in chromosome stability and DNA
repair processes (19). Together, this indicates that the tumor
suppressive function of PTEN is partly mediated through its
nuclear localization and/or retention.
Despite ample evidence indicating that PTEN localizes in
the nucleus (7,17,20), PTEN contains neither a traditional
nuclear localization signal (NLS) nor a nuclear export signal
(NES). Several methods have been implicated in modulating
PTEN localization; however, these appear to be cell type
dependent. These include passive diffusion (18), a putative
cytoplasmic retention signal (6), transport mediated by either
the Ran GTPase (7), or Major Vault Protein (MVP) (5,21),
phosphorylation-dependent shuttling (7), monoubiquitination-
dependent import (8) and S6K-mediated export (22). Recently,
we have shown that intracellular localization of PTEN can be
modulated by ATP levels (23). However, the exact mechanism
remained unknown. Interestingly, other proteins whose subcel-
lular localization is modulated by ATP, such as Hsc70 and
nucleophosmin/B23, bind ATP through consensus ATP-
binding domains (24–26).
We, therefore, hypothesize that since the intracellular local-
ization of PTEN is modulated by ATP, PTEN can bind to ATP
and that this interaction could inﬂuence its intracellular local-
ization. In this study, we sought to examine the ATP-binding
capabilities of PTEN, and to evaluate the importance of germ-
line CS-related PTEN mutations and cancer-derived somatic
PTEN missense mutations occurring within these ATP-binding
sites in inﬂuencing nuclear PTEN localization and function.
RESULTS
Speciﬁc somatic misssense mutations affect PTEN
localization, cellular growth and proliferation in vitro
We, and others, have shown that PTEN can be localized to
both the cytoplasmic and nuclear compartment (6–
8,17,23,27). Putative sites in PTEN have been postulated to
be important in regulating nuclear localization, such as those
shown in vitro to bind to MVP, one PTEN-interacting
protein which mediates nuclear import (5,21), and those that
mediate ubiquitination and genomic stability (8,19).
However, naturally occurring PTEN mutations found within
the latter two are extremely limited. We were surprised to
note that PTEN was found to be mislocalized in the nucleus,
by immunohistochemistry, in sporadic primary colorectal car-
cinomas harboring the K62R, Y65C and K125E missense
mutations (9); yet, the three somatic mutations found in
these primary tumors were not speciﬁcally located in any of
the known regions within PTEN believed to be important for
nuclear localization, as noted above.
To explore the effects of these mutations further, we
modeled these mutations in vitro. We generated FLAG-tagged
protein as described in the Materials and Methods. Subcellular
localization of these mutant proteins was performed utilizing
both immunoﬂuorescence and western analysis. We found
that transiently transfected full-length over-expressed
WTPTEN localized to both the cytoplasmic and nuclear com-
partments in MCF7 cells as previously described (Fig. 1A)
(5,17). However, when we analyzed the sporadic carcinoma-
derived somatic mutations in transfected MCF7 cells, we
found that the K62R (pK62R-FLAG) and Y65C
(pY65C-FLAG) mutant PTEN displayed a predominant
nuclear accumulation, when compared with WTPTEN
(Fig. 1A) as evidenced by DAPI counterstaining (Fig. 1A,
panels c, f, i and l). The K125E mutant PTEN
(pK125E-FLAG) also showed a preference towards nuclear
accumulation. However, this localization was not as strong
as that observed in cells expressing either the K62R or
Y65C mutant PTEN (Fig. 1A). Nevertheless, the K125E
mutant PTEN localized to the nuclear compartment to a
greater extent than WTPTEN.
Using biochemical techniques, we found that over-
expressed WTPTEN (pWTPTEN-FLAG) can be detected in
both cytosolic and nuclear fractions after western blot
(Fig. 1B). Exogenously expressed K62R, Y65C and K125E
PTEN mutants showed an increase in nuclear fraction
protein levels, when compared with WTPTEN (Fig. 1B). In
concordance with the immunoﬂuoresence data, the K62R
and Y65C PTEN mutants showed the highest amount of
nuclear PTEN protein accumulation (Fig. 1B).
It has been suggested that proper cellular localization, or
more accurately proper balance between nuclear and cyto-
plasmic localization, of PTEN regulates cellular proliferation
(4,6,7,27). Thus, we examined the effect of overexpression
of these PTEN mutants on proliferation. As expected, overex-
pression of WTPTEN, in MCF7 cells, markedly reduced the
rate of cell proliferation, when compared with the parental
cell line or to cells transfected with vector control (Fig. 2A
and B). In contrast, MCF7 cells overexpressing the cancer-
associated PTEN mutants, K62R, Y65C or K125E, had pro-
liferation rates similar to, or higher than, that of the vector
only control. MCF7 cells overexpressing the K125E mutant
PTEN had the highest rate of proliferation (Fig. 2A and B).
This suggests that these mutants do, indeed, have a functional
effect, at least in vitro.
We also analyzed the level of anchorage-independent
growth, a hallmark of cellular transformation, utilizing
colony formation in soft agar/agarose (6). MCF7 cells overex-
pressing WTPTEN had a signiﬁcantly reduced ability to grow
in soft agarose when compared with vector only and non-
transfected parental MCF7 cells (Fig. 2C). In contrast,
MCF7 cells expressing the K62R, Y65C or K125E PTEN
mutant protein exhibited a capacity for anchorage-independent
2852 Human Molecular Genetics, 2009, Vol. 18, No. 15growth that was greater than that produced by the vector only
expressing MCF7cells (Fig. 2C). Interestingly, cells expres-
sing the K125E mutant PTEN protein produced the highest
number of colonies (Fig. 2C). Cells expressing the Y65C
mutant PTEN had the lowest level of anchorage-independent
growth of the three mutant expressing lines, however colony
formation was still higher than colony formation found in
cells overexpressing WTPTEN. Interestingly, we also
observed a difference in colony size in MCF7 cells overex-
presing either K62R mutant PTEN or Y65C mutant PTEN
when compared with the vector only and cells overexpressing
K125E mutant PTEN (Fig. 2D).
It is well known that overexpression of WTPTEN induces
G1 growth arrest and/or apoptosis in a cell type-dependent
manner (4,17,27). Thus, we examined the effect of these
three mutations on G1 arrest. While overexpression of
WTPTEN resulted in a 40–50% increase in G1 arrest, when
compared with parental or vector only transfected cells
(Fig. 2E), MCF7 cells overexpressing any of the mutant
PTEN proteins exhibited a decreased level of G1 arrest
when compared with WTPTEN (Fig. 2E). Indeed, the level
of G1 arrest exhibited in cells expressing the K125E mutant
was even lower than those observed with the vector only
control transfected cells (Fig. 2E). Using the TUNEL assay,
we found that overexpression of WTPTEN led to a 5-fold
increase in the number of apoptotic cells (Fig. 2F and G) com-
pared with control cells. In contrast, cells overexpressing
either K62R or Y65C mutant PTEN had reduced apoptotic
capabilities (Fig. 2F and G), while the K125E mutant PTEN
was unable to induce any apoptosis (Fig. 2F and G).
PTEN contains ATP-binding motifs in the N-terminal
phosphatase domain
The above data indicate that the carcinoma-derived somatic
PTEN mutations not only show increased nuclear retention,
but also are highly pro-proliferative and induce a loss of
growth-inhibitory activity, in contrast to those cells expressing
WTPTEN. Further, this appears to be related to the nuclear
localization of these mutant proteins. However, it is not
readily apparent how these mutations affect nuclear localiz-
ation. We have recently shown that PTEN localization can
be modulated by intracellular ATP levels (23). Proteins that
are regulated by ATP often contain consensus ATP-binding
Figure 1. Neoplasia-derived PTEN mutants results in increased nuclear PTEN localization. (A) MCF7 cells were transfected with either wild-type (WT) PTEN
or individual PTEN missense mutants and subjected to direct immunoﬂuorescence analysis using a a-FLAG antibody, as indicated. PTEN expression is detected
as green ﬂuorescence. Nuclei were also concurrently stained with DAPI, which was included in the mounting medium. Representative images showing the local-
ization of WT and each mutant PTEN are shown. All experiments were carried out in duplicate. Approximately 100 cells were counted per individual transfec-
tion and representative images from three separate experiments are shown. All images were acquired at  63 magniﬁcation. (B) MCF7 cells were transfected
with either WT or mutant PTEN as indicated. Approximately 40–48 h post transfection, cells were harvested and subjected to subcellular fractionation as pre-
viously described (C, cytoplasmic protein; N, nuclear protein) and were analyzed by SDS–PAGE and western blotting.
Human Molecular Genetics, 2009, Vol. 18, No. 15 2853Figure 2. Neoplasia-derived PTEN mutations result in a loss of growth suppressive activity. (A and B) The proliferation capacity of MCF7 cells stably expres-
sing wild-type (WT) or mutant PTEN was assessed post-Tet release using the XTT (A) or soft agar (B) assay. Data shown corresponds to the average cell number
(with SD). (C and D) Cell lines expressing WT or mutant PTEN were assessed for anchorage independent growth using a soft agarose colony assay. (C) A
representative image of soft agarose colonies formed by MCF7 cells stably expressing either the WT or mutant PTEN (taken at  4 magniﬁcation), data
shown corresponds to the average number of colonies formed (with SD) after 2 weeks. (D) The average areas of individual colonies (in pixels) were calculated
using the ImagePro Plus software and plotted as a box and whisker plot. The line inside each data box represents the mean colony area or size. The sizes of
approximately 100–120 colonies were measured for each mutant (E–G) Neoplasia-derived PTEN mutations affect apoptosis and cell cycle. (E) After induction
of PTEN expression, MCF7 cells were ﬁxed, and DNA content was determined using ﬂow cytometry with PI staining. Data from one of the three replicates of
each experiment is shown. The three PTEN mutant overexpressing MCF7 cells show reduced G1/S ratio, as compared to the WTPTEN, (F and G) MCF7 cells
stably overexpressing WT or mutant PTEN were grown in the absence of Tetracyclin (TetOff) to induce PTEN expression (for 96 h). Cells were ﬁxed, and the
number of cells undergoing apoptosis was determined using the TUNEL assay followed by ﬂow cytometric analysis. Data from one of the three replicates of each
experiment is shown.
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PTEN’s amino acid sequence contains two putative ATP-
binding sequences (28,29), in the N-terminal phosphatase
domain of the protein (Fig. 3A and B). A Type-A consensus
ATP-binding sequence resides at amino acid residues 125–
128 (Fig. 3A) and a Type-B consensus ATP-binding sequence
resides at amino acid residues 60–73 (Fig. 3B). Both of these
sites are located with PTEN’s N-terminal phosphatase domain
and interestingly the somatic-derived mutations that have
altered PTEN nuclear localization occur within these regions.
Endogenously expressed WTPTEN binds to ATP–agarose
The binding of proteins to immobilized ATP has been taken as
evidence for the association of various proteins with ATP
(24,28,29) as has been well documented for the ATP-binding
protein Hsc70 (28). We found that like Hsc70, WTPTEN
binds to ATP (Fig. 4A). In ATP-binding assays, PTEN
protein is not found in the ATP–agarose washes (Fig. 4A;
W1 and W2), but was found eluted from the ATP–agarose
with buffer containing ATP (Fig. 4A; ATP elution). This
strongly suggests that, similar to a known ATP-binding
protein (Hsc70), PTEN binds ATP.
Carcinoma-associated PTEN mutations in the
ATP-binding regions show reduced ATP binding
As alluded to above, the somatic PTEN mutations identiﬁed
from primary sporadic colorectal tumors (K62R, Y65C and
K125E) occur within PTEN’s putative ATP-binding sites
(Fig. 3A and B). Therefore, we examined whether these
mutant PTEN proteins could bind to ATP, utilizing the
various overexpressing cell lines utilized in the growth
assays described earlier.
Figure 3. Consensus ATP-binding motifs in the N-terminal phosphatase
domain of PTEN. Comparison of known consensus ATP-binding motifs to
putative ATP-binding motif sequences in the N-terminal domain of PTEN.
(A) A putative Type-A ATP-binding motif lies within exon 5, (B) A putative
Type-B ATP-binding motif resides within exon 3. Germline (highlighted in
red) and cancer-derived PTEN mutations analyzed in this study are highlighted
in bold and underlined.
Figure 4. PTEN binds ATP that can be disrupted by missense mutations. (A)
Total protein (1–2 mg) was extracted from MCF7 cells and subjected to ATP-
binding assay as described in Materials and Methods. Dissociation of speciﬁ-
cally bound protein to ATP was initiated by the addition of buffer A contain-
ing 1 mM ATP and 0.5 M KCl to the ATP–agarose. Samples were
concentrated and analyzed by SDS–PAGE and western analysis for PTEN
and a Hsc70. L, crude protein load; S, supernatant; W1, supernatant from
wash 1 using buffer A only; W2, supernatant from wash 2 using buffer A þ
0.5 M KCL; ATP elution; supernatant retained after wash with 1 mM
ATP þ 0.5 M KCl, (B) Cancer-associated PTEN mutants showed reduced
ATP binding. Total protein from MCF7 cells stably expressing either the
WTPTEN or mutant PTEN was used in an ATP-binding assay. Both endogen-
ously expressed, and exogenously introduced (FLAG-tagged) WTPTEN
showed strong ATP binding in comparison to the cancer-derived PTEN
mutants, (C) MCF7 cells stably expressing WTPTEN or mutant PTEN were
subjected to subcellular fractionation and used in ATP-binding assays.
Exogenously expressed WTPTEN shows strong ATP binding in both the cyto-
plasmic and nuclear fractions; while the cancer-derived PTEN mutants showed
signiﬁcantly reduced ATP binding in both compartments. Note that K62R- and
K125E-PTEN mutants show little to no ATP binding in the nuclear fractions
(no bands in nuclear fraction-eluate) although they show predominant nuclear
localization (see Fig. 1).
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PTEN (WT and mutants) protein at similar levels (data not
shown). We found that in all the cell lines, endogenous
PTEN bound efﬁciently to ATP, as expected (Fig. 4B). In con-
trast, we found that mutant PTEN protein did not bind to ATP
as well as WTPTEN. There was less mutant PTEN detected in
the ATP elute, when compared with the FLAG-tagged
WTPTEN (Fig. 4B). These mutations, however, did not com-
pletely abolish ATP binding. In order to examine this in more
detail, we performed ATP-binding assays on both cytosolic
and nuclear fractions from cell lines expressing the mutant
PTEN proteins. Endogenous nuclear and cytosolic WTPTEN
efﬁciently bound to ATP (Fig. 4C). In addition, exogenously
expressed nuclear and cytosolic FLAG-tagged WTPTEN
bound to ATP (Fig. 4C). However, all exogenously expressed
mutant PTEN showed reduced ATP binding, with the K62R
and K125E mutant PTEN nuclear proteins showing little to
no nuclear ATP-binding capability (Fig. 4C), despite the fact
that these mutant proteins are predominately nuclear when
compared with WTPTEN (Fig. 1A and B). This may suggest
that ATP binding is required for PTEN nuclear export.
Germline PTEN mutations located in the ATP-binding
domains identiﬁed in CS patients
Our above data suggest that PTEN mutations located in the
putative ATP-binding domains not only reduce the ability of
PTEN to bind ATP, but also modulate PTEN protein in a det-
rimental manner. It stands to reason, then, that germline
mutations in the ATP-binding sites may occur in patients
with CS. Of the 400 classic CS patients, we found at least
4 CS patients with germline PTEN missense mutations that
occur in the midst of these putative ATP-binding sites
(Fig. 3A and B). It should be noted, however, that missense
mutations in CS are less common than truncating ones, but
of 20 different germline missense mutations in PTEN,
14 lie in these two putative ATP-binding sites. Two patients
had germline mutations in the Type-A binding site: R130G
and R130Q. Additionally, two patients had germline mutations
in the B-Type ATP-binding site: Y68H and Y68C. Each of
these mutations are novel missense mutations, which are
highly predicted to be deleterious, although this has not been
conﬁrmed functionally. Using patient-derived lymphoblastoid
lines from the four CS probands, we examined the subcellular
localization of PTEN in these patient samples. Lymphoblas-
toid cell lines from patients with putative ATP-binding site
mutations demonstrated an increase in PTEN nuclear protein
when compared with control lymphoblastoid lines (Fig. 5).
These CS patients consisted of three females and one male.
Interesting, all three females had breast cancer.
DISCUSSION
We recently reported that intracellular localization of PTEN is
modulated by ATP levels (23). In our previous study, it was
not readily apparent if ATP was modulating export or if
there was an inhibitory phosphorylation event occurring. Our
data here demonstrate that PTEN can bind ATP and somatic
and germline-derived mutations in the ATP-binding sites
result in PTEN being retained in the nuclear compartment,
suggest that ATP is necessary for PTEN nuclear export.
In the ATP-binding domain of nucleophosmin/B23, the
positively charged lysine residues, in particular lysine263,
not only inﬂuences ATP-binding capabilities but also inﬂu-
ences the subcellular localization of nucleophosmin/B23
(24,25,29). This suggests that positively charged residues are
important in ATP binding. The PTEN consensus ATP-binding
domain, identiﬁed here, contains several positively charged
residues, including lysine residues (Fig. 3 and Supplementary
Material, Fig. S1). Indeed, like nucleophosmin/B23, we found
that naturally occurring germline and somatic mutations of
these residues resulted in decreased ATP binding (Fig. 4 and
Supplementary Material, Fig. S2) and altered localization of
PTEN compared with WT protein (Fig. 5). Of importance,
we found this in a variety of cell types (Supplementary
Material, Fig. S3). Our data suggest that not only the posi-
tively charged amino acid residues (lysine 62, lysine 125
and arginine 130), but also the polar uncharged residues (tyro-
sine 65 and tyrosine 68) in PTEN’s consensus ATP-binding
domain are important for ATP binding.
Independent of our study, Gil et al. (7), and more recently,
Denning et al. (6), have demonstrated that the amino acid resi-
dues in the N-terminal phosphatase domain of PTEN can
potentially behave either like nuclear exclusion or cytoplasmic
retention motifs. Additionally, mutation of the hydrophobic
tyrosine residues within the N-terminal region of PTEN (resi-
dues 1–32) inﬂuence its nuclear localization in U87MG glio-
blastoma cells in a RanGTPase-dependent manner (7).
However, a precise mechanism for this action was not fully
elucidated. It is interesting to hypothesize, based on our
data, that these regions contain speciﬁc charged residues that
may be involved in ATP binding. Mutation of the lysine
Figure 5. Lymphoblastoid lines from CS patients with germline ATP-binding
PTEN mutations have altered PTEN localization. Lymphocytes from CS
patients with germline PTEN mutations, occurring within the PTEN ATP-
binding domains, were subjected to nuclear-cytoplasmic protein fractionation
and then analyzed by SDS–PAGE and western blotting. Western blotting for
PARP-1 (nuclear speciﬁc protein) or a-tubulin (cytoplasmic speciﬁc protein)
is shown.
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duction of an additional positive charge, which may require
more energy for ATP to dissociate. This may explain the
increased nuclear retention of the K62R-PTEN mutant in
various cell lines tested (Fig. 1 and Supplementary Material,
Fig. S3). Similarly, the change at residue 65 and 68 from tyro-
sine to cysteine may provide for the opportunity of an
additional disulphide (-SH) bond, which could require more
energy for cellular trafﬁc. In contrast, mutation of PTEN at
amino acid residues 130 (R130G and R130Q) leads to a loss
of a positive charge versus a gain. Clearly, the physical chem-
istry involved in these mutations and its affect on localization
mechanisms requires further study.
Previous work, by others and us, has suggested that nuclear
PTEN is required for proper cellular proliferation and growth
(4–8). More accurately, we believe that the balance of nuclear
to cytoplasmic (WT) PTEN is important. Indeed, loss of
nuclear WTPTEN has been correlated with unrestrained
growth and tumor formation and progression. For example,
when analyzing the subcellular localization of PTEN in mela-
noma, we found that 30/30 metastatic melanomas had loss of
nuclear PTEN protein expression (11). This suggests that
nuclear expression of WTPTEN is necessary for growth regu-
lation and provides a protective effect in the cell, which has
been supported in thyroid, breast and pancreatic islet
models. Thus, it is interesting to note that in this study,
mutations identiﬁed in colorectal cancer, alter PTEN: ATP
binding and result in an increase in nuclear PTEN protein.
This increase resulted in phenotypes, such as growth in soft
agarose, which may be detrimental and not protective, as
might have been expected. One hypothesis is that atypical
increases in nuclear PTEN, which is also mutant, prevent
normal cytosolic PTEN function. It is not unreasonable to con-
sider the possibility that PTEN has unrecognized functions in
the nucleus, as, until now, it was not known that PTEN could
bind ATP. Our data indicate that proper regulation of PTEN:
ATP binding is necessary for correct cellular growth.
Whether this is simply due to alterations in nuclear transport
or other signaling or protein:protein interactions remains to
be determined. Undoubtedly, more remains to be elucidated
regarding alternative PTEN functions, particularly those that
require the binding of ATP. Nonetheless, PTEN regulation/
function may not simply be a matter of localization, and
while this may create a more confusing scenario it also pro-
vides other areas to target for novel therapeutics.
We have identiﬁed two putative ATP-binding sites in PTEN
(Fig. 3). These sites are in areas that are highly conserved
among a variety of species (Supplementary Material,
Fig. S4), underlining the importance of these sites. Indeed,
our data with sporadic- and germline-derived PTEN mutations
strongly indicate that these mutations are pathologic. We
found, that of four unrelated CS patients, that the three
female patients all had breast cancer. While the sample size
is small, overall functional, genetic and phenotypic data
suggest that these mutations are pathogenic.
Taken together with our previous data, we demonstrate that
PTEN binds ATP. The binding of PTEN to ATP not only con-
trols nuclear localization, likely through the modulation of
nuclear export, but also further regulates cellular functions
such as abrogation of PTEN’s tumor suppressor capabilities.
This is supported not only by the somatic mutations identiﬁed
in sporadic primary colorectal tumors, but also by the identiﬁ-
cation of four CS patients with germline ATP-binding domain
missense mutations. In contrast, mutation of the bipartite
NLS-like sequences which bind MVP do not result in altera-
tions in phosphatase function (21). Because naturally occur-
ring PTEN missense mutations outside the ATP-binding
motifs do not result in abrogation of ATP binding nor
nuclear mislocalization (Supplementary Material, Fig. S5
and S6), we believe that it may be both the presence of a
mutation and the resulting nuclear mislocalization that are
important. Whether it is any mutation in the ATP-binding
motifs or whether it is the change in charge within the
motifs that are important in nuclear mislocalization is not
entirely known. Neutral mutations of our three
somatic-associated ATP-binding motif mutations do result in
some mislocalization to the nucleus (over WTPTEN), but
slightly less so than the mutations which change the charge
of those residues as well (Supplementary Material, Fig. S7
versus Fig. 1A). Thus, we may conclude that disruption of
ATP binding is the major etiology for nuclear PTEN retention
while charge plays a secondary role to determine the extent.
Initially, at a superﬁcial level, our data may appear contra-
dictory to previous observations that predominant nuclear
expression of PTEN is seen in normal cells. However, it
should be noted that normal cells have a predominance of
nuclear PTEN and all of their PTEN is WT. WTPTEN in
the nucleus signals down its protein phosphatase activity via
cyclin D1 to downregulate MAPK signaling and elicit G1
cell cycle arrest and to stabilize the genome (16,19). Our
current observations, therefore, suggest that mutant PTEN
mislocalized in the nucleus prevents G1 arrest probably
through upregulation of MAPK signaling and downregulation
of cyclin D1. This hypothesis is corroborated by our cell cycle
data presented here.
Missense mutations, as opposed to truncating mutations, are
often conservatively interpreted as variants of unknown sig-
niﬁcance until proven otherwise. Thus, these observations
should also aid in the genetic counseling of patients with
germline PTEN missense mutations that lie anywhere in the
ATP-binding domains. Together with the recent observation
that germline variants in the genes encoding mitochondrial
complex II subunits succinate dehyrogenase B and D
(SDHB, SDHD) occur in PTEN mutation negative CS pro-
bands (30), our data here add to the importance of energy
and energy production in both heritable and sporadic neopla-
sias where the PTEN pathways are relevant. These obser-
vations should provide a novel pathway which involves
manipulation of ATP and mitochondrial function in the treat-
ment of both these heritable and sporadic malignancies.
MATERIALS AND METHODS
Materials
Platinum Pfx polymerase, hygromycin, T4 DNA ligase,
Prolong Gold anti-fade mounting medium and MAX efﬁ-
ciency DH5a competent cells were purchased from Invitrogen
(Carlsbad, CA). The XTT cell proliferation kit was obtained
from Roche (Indianapolis, IN). The mammalian expression
2858 Human Molecular Genetics, 2009, Vol. 18, No. 15vector pCMV-FLAG-5b, a-FLAG M2 FITC-conjugated anti-
body, a-FLAG antibody, ATP–agarose, protease inhibitors
(cocktail), phosphatase inhibitors (cocktail 1 and 2) and paraf-
ormaldehyde (PFA) were purchased from Sigma Chemical Co.
(Portland, OR). Restriction endonucleases were obtained from
New England Biolabs (Ipswich, MA). The QuickChange
in vitro site-directed mutagenesis system and XL-1 blue super-
competent cells were from Stratagene (La Jolla, CA, USA).
DMEM and RPMI medium were obtained from GIBCO
BRL (Hercules, CA, USA). The M-PER and NE-PER
protein extraction kits and the BCA protein assay kit were
from Pierce Biotechnology Inc. (Rockford, IL, USA).
Sample concentration columns used were Millipore
Biomax-30 kDa NMWL Centrifugal Filters (Millipore, Biller-
ica, MA). Antibodies used were a-PTEN monoclonal antibody
clone 6H2.1 (Cascade Biosciences, Portland, OR, USA),
a-Hsc70, a-tubulin and PARP-1 (Cell Signaling Technol-
ogies, Danvers, MA, USA). All primers were obtained from
Sigma Genosys (Portland, OR, USA). All other chemicals/
reagents were obtained from common commercial sources.
Patients
We utilized peripheral blood samples accrued from four CS
patients with germline mutations in the ATP-binding domain
of PTEN. Classic CS was diagnosed when the operational
diagnostic criteria of the International Cowden Consortium
was met (1). We also utilized peripheral blood samples from
four normal populational controls, which were anonymized
prior to storage and analysis. Informed consent was obtained
for all subjects (CS individuals and controls) in accordance
with procedures and protocols approved by the respective
Human Subjects Protection Committee of each participating
institution. All subjects, whether CS or controls, participated
on a voluntary (unpaid) basis.
Mutation analysis
Genomic DNA extracted from peripheral leukocytes, obtained
from both CS patients and controls, were ampliﬁed by PCR
and subjected to direct sequencing (ABI3730xl) of all PTEN
exons and ﬂanking introns, as previously described by
us (31). All controls had no detectable PTEN sequence
alterations.
Cell lines, culture conditions and reagents
Human immortalized lymphoblast cell lines obtained from CS
patients and controls were cultured in high-glucose RPMI
1640 supplemented with 20% fetal bovine serum (FBS), 1%
penicillin–streptomycin sulfate and maintained at 378C and
5% CO2. MCF7 and MDA-MB-231 breast carcinoma cell
lines and WM164 cutaneous melanoma cell lines were main-
tained in high-glucose DMEM supplemented with 10% FBS
and 1% penicillin–streptomycin sulfate. The HT29 colorectal
cancer cell line was maintained in high-glucose RPMI 1640
supplemented with 10% FBS and 1% penicillin–streptomycin
sulfate. All cell lines were maintained at 378C and 5% CO2.
All cell lines were screened for PTEN mutations in the
coding, ﬂanking intronic and promoter regions using both
DGGE and automated sequencing and contain the
WTPTEN. MCF7 cells stably over-expressing either
WTPTEN (TetWTPTEN) or mutant PTEN K62R
(TetPTEN-K62R), Y65C (TetPTEN-Y65C) and K125E
(TetPTEN-K125E) were generated as described below and
grown in the presence of tetracycline (Tet), unless otherwise
indicated. All plasmids generated contain a FLAG epitope at
the C-terminus such that the expressed PTEN contains a C-
terminal FLAG fusion.
ATP–agarose-binding assay
ATP–agarose was used in a binding procedure as previously
described with minor modiﬁcations (28,29,32). Brieﬂy,
ATP–agarose (8 mg) was equilibrated with buffer A (40 mM
HEPES, pH 7.5, containing 20 mM KCl, 5% glycerol and
5m M MgCl2). Approximately 1–4 mg of protein was mixed
with equilibrated ATP–agarose in a total volume of 1 ml
buffer A. The protein–ATP–agarose mixture was then incu-
bated for 24 h at 48C with rotational mixing. The mixture
was then centrifuged at 14 000 rpm for 10 min and the resul-
tant supernatant (S) retained on ice for further analysis. The
ATP–agarose was washed ﬁve times with 1 ml of buffer A
each time. After each wash the mixture was centrifuged and
the supernatant retained on ice (wash 1, total volume 5 ml).
The agarose pellet was washed a further ﬁve times with high
salt buffer (buffer A þ 0.5 M KCl). The sample was centri-
fuged between washes and the supernatant was retained after
each wash (wash 2, total volume 5 ml). Finally, dissociation
of protein speciﬁcally bound to ATP was initiated by the
addition of buffer A containing 1 mM ATP and 0.5 M KCl
(ATP elution). The supernatants retained after each wash, or
elution, were concentrated using the Millipore Biomax-30 kDa
NMWL centrifugal ﬁlters (Millipore). Approximately 30 mlo f
concentrated sample was electrophoresed on 10% SDS–
PAGE gels as previously described (23), and immunoblotted
using the respective antibodies as indicated.
WTPTEN plasmid construction
Total RNA (1 mg) was reverse transcribed using the Super-
Script One-Step RT–PCR for Long Templates system and
ampliﬁed using high ﬁdelity Pfx DNA polymerase essentially
as described by the manufacturer (Invitrogen). The full-length
PTEN open-reading frame was ampliﬁed by RT–PCR, pre-
pared from total RNA, using the primers PTENAtgFwd
(50-CGCGAATTCGCCACCATGACAGCCATATC-30) and
PTENTgaRev (50-TACCGGA TCCACTTTTGTAATTTG-30)
containing ﬂanking EcoR1 and BamH1 restriction sites,
respectively. The forward primer contained a Kozak sequence
(GCCACC) to facilitate expression. The ampliﬁed PTEN
cDNA sequence was then sub-cloned into the EcoR1 and
BamH1 sites of the mammalian expression vector
pFLAG-CMV-5b containing a 30 FLAG tag which would be
fused to the C-terminus of the expressed PTEN. Ligation
was carried out using T4 DNA ligase at an insert: vector
molar ratio of 3:1. Native and recombinant plasmids were
transformed into supercompetent DH5a cells according to
the manufacturer’s instructions (Invitrogen). After plasmid
midi/ maxi-preparation, plasmid DNA was digested with
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the insert. The appropriate construction of the FLAG-tagged
WTPTEN cDNA clone (pWTPTEN-FLAG) was veriﬁed by
sequence analysis on both strands.
Preparation of PTEN mutant constructs
The WTPTEN cDNA clone in pFLAG-CMV-5b (pWTPTEN-
FLAG) was used as the template to engineer each of the PTEN
mutations (K62R, Y65C and K125E) previously identiﬁed by
us in primary colorectal tumors (9). Each PTEN mutant
(pK62R-FLAG, pY65C-FLAG and pK125E-FLAG) was
engineered using the QuickChange in vitro site-directed muta-
genesis system according to the manufacturer’s instructions
(Stratagene) using the following mutagenic primers:
pK62R-FLAG-Fwd (50GGTTT TTGGATTCAAAGCATA-
GAAACCATTACAAGATATACA ATC-30) with
pK62R-FLAG-Rev (50-GATTGTATATCTTGTAATGGTTT
CTATGCTTTGAA TCCAAAA ACC-30); pY65C-FLAG
-Fwd (50-GGATTCAAAGCTAAAAACCATTGCAAGA
TAT ACAATCTTTGTGC-30) with pY65C-FLAG-Rev (50-G
CACAAAGATTGTATATCTTG CAATGGTTTTTATG
CTTTGAATCC-30) and pK125E-FLAG-Fwd (50-ATGTTG
CAGCAAT TCACTGTGAAGCTGGAAAGGGACGAACT
GGTG-30) with pK125E-FLAG-Rev (50-CACCAGTT CGT
CCCTTTCCAGCTTCACAGTGAATTGCTGCAACAT-30).
The corresponding mutagenic bases are indicated in the bold
and are underlined type. The appropriate construction of the
FLAG-tagged mutant PTEN plasmid(s) was veriﬁed by
sequence analysis of both strands using the pFLAG-CMV-5b
vector primers.
Transient transfection and cellular analysis
Cells were either grown on coverslips in 6-well plates (for sub-
cellular localization assays) or cultured in 100 cm
2 dishes (for
western analysis) and were transfected with 3–6 mg of puri-
ﬁed plasmid DNA (WTPTEN or PTEN mutant) using either
LipofectAMINE 2000 or FuGENE6 and Opti-MEM according
to the manufacturer’s instructions. Brieﬂy, the plasmid DNA
in Opti-MEM was mixed with either LipofectAMINE or
FuGENE6 and incubated at room temperature for 20 min to
allow formation of lipid-DNA complexes. After incubation,
the DNA-LipofectAMINE/ FuGENE6-OptiMEM lipid
complex was gently added drop wise onto the cells on the cov-
erslips, or in the culture dishes, and the cells were then over-
layed with the appropriate culture medium.
Generation of stable Tet-Off cell lines
Stable cell lines with Tet-regulated PTEN expression were
generated according to the manufacturer’s protocol (Clontech
Protocol No. PT3001-1). Brieﬂy, the pTetOff vector contain-
ing the tTA regulatory element was transfected into the
MCF7 parental line and placed under G418 selection. Resist-
ant colonies were then isolated and expanded. Expanded
clones were transiently transfected with pTRE2Hyg-luc in
the presence or absence of Tet and luciferase levels were
measured after 48 h. Clones showing an induction of lucifer-
ase activity in the absence of Tet were transfected with the
WTPTEN cDNA construct cloned into the pTRE2Hyg
vector (TetWTPTEN). Cells were grown under hygromycin
selection in the presence of Tet and resistant colonies isolated
and expanded. Tet-regulated expression of exogenous PTEN
was conﬁrmed by western analysis on total protein lysates col-
lected from cells grown in the presence or absence of Tet. The
TetWTPTEN construct was used as the template to engineer
each of the individual mutations (TetPTEN-K62R-FLAG,
TetPTEN-Y65C-FLAG and TetPTEN-K125E-FLAG) to be
tested. Each mutant was engineered using the QuickChange
in vitro site-directed mutagenesis system (Stratagene) accord-
ing to the manufacturer’s instructions using the primers
described earlier. The appropriate construction of the FLAG-
tagged mutant PTEN plasmids were veriﬁed by sequence
analysis using vector primers as described above.
Direct immunoﬂuoroscence and confocal microscopy
Approximately 40–48 h post transfection, cells grown on cov-
erslips were ﬁxed in a freshly prepared mixture of methanol:a-
cetone (1:1 ratio) for 1 min at room temperature. Cells were
washed thrice with Tris-buffered saline (TBS) and then incu-
bated with the a-FLAG M2 FITC-conjugated antibody
(1:500 dilution in TBS) at room temperature for 1 h. After
further washing of the cells with TBS, the coverslips were
mounted face down onto glass slides (Labtek Inc., Grand
Rapids, MI) with a small drop of ProLong Gold antifade
mounting medium containing DAPI. Cells were then exam-
ined at room temperature under a Leica DM RXE (TCS-SP/
SP-AOSB) confocal microscope with HCX Plan 63  numeri-
cal aperture 1.4 oil immersion objective lens, using Leica con-
focal software version 2.5 (Leica, Wetzler, Germany).
Confocal images were acquired as Z stacks or single XY sec-
tions. For merged images, projections of image stacks were
prepared in Velocity version 3.7.0 (Improvision, Coventry,
UK). All experiments were carried out in duplicate. Approxi-
mately 100 cells, from 10–15 ﬁelds, were counted and scored
per transfection. Note should be made that visualization of
relative intensities, by the human eye, of indirect immuno-
ﬂuorescence is different from that of standard immuno-
histochemistry. While relative intensity in indirect
immunoﬂuorescence to the human eye appears more linear
(it is not linear in reality), relative intensity of staining from
immunoﬂuorescence is non-linear and the human eye is only
able to detect an intensity increase or decrease only after
quite a large (non-linear) increase or decrease. Because of
the histological view of cells (which is two-dimensional)
with the very much smaller nuclear area compared with the
cytoplasmic area, relative nuclear expression of any protein
will be very exaggerated (i.e. look very strong) when com-
pared with an equal amount of that protein in the cytoplasm
(with its much larger surface area). Hence, visualization of
relative intensities between a histological approach and
western blot will appear different to the human eye. Because
total protein content is very much higher in the cytoplasm
over that from the nucleus, the very reason why a two-
dimensional imaged cell (compared with western blot)
shows intense nuclear staining is also the reason why cyto-
plasmic proteins which mainly reside in one compartment
(in PTEN’s case, the cytosol) will always appear more
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studied, the majority of PTEN is localized to the cytoplasm
with a small, but distinct, portion present in the nucleus.
Subcellular fractionation, protein isolation and western
blot analysis
Total, nuclear and cytoplasmic proteins were isolated at the
indicated time-points as previously described (21,23), using
either the M-PER (total protein) or NE-PER (nuclear-
cytoplasmic protein) extraction reagents according to the man-
ufacturer’s instructions (Pierce). Proteins obtained either from
cell lines or cultured lymphocytes were fractionated on 10%
SDS–PAGE gels using either the BioRad Mini-gel or the Cri-
terion system and transferred to nitrocellulose. Equal protein
loading was conﬁrmed by staining the nitrocellulose blots
with Ponceau S and by western analysis with a-tubulin (cyto-
solic protein) or a-PARP-1 (nuclear protein). Blots were
probed with a-PTEN, a-FLAG, a-Hsc70 and a-actin, each
at a 1:1000 dilution, followed by incubation with the appropri-
ate secondary antibody and visualized using enhanced chemi-
luminescence detection.
Colony-forming assay
To evaluate the transforming potential of the PTEN mutants,
anchorage-independent growth was measured by soft agarose
colony assay as previously described, but with minor modiﬁ-
cations (4). Brieﬂy, the assay was performed in 60 mm
dishes with a base of 2.5 ml of 2  DMEM medium containing
0.4% agarose and 5% FBS. Stably expressing, tetracyclin
released (TetOff) WTPTEN and PTEN mutant expressing
MCF7 cells were seeded, in duplicate, in 2 ml of 2 
DMEM containing 5% FBS with 0.4% agarose at 2  
10
4 cells/ml and layered onto the base. These embedded
cells were then overlayed with 1 ml of 1  DMEM and 10%
FBS. Culture dishes were incubated at 378C and 5% CO2
for approximately 2 weeks (overlayed media was replenished
as required), and the diameter of the tumor colonies formed
were determined using a microscope equipped with an
ocular scale in the eyepiece. The average area of individual
colonies were calculated (in pixels) using the ImagePro Plus
software as previously described (33). Approximately 100–
120 colonies were counted and sized. All experiments were
carried out in triplicate.
Cell proliferation assay
Stably expressing, Tet released (Tet-Off) WTPTEN and PTEN
mutant expressing MCF7 cells were seeded, in triplicate, in
96-well cell culture plates at a density of 2   10
4 cells per
well in 100 ml of culture medium and incubated at 378C
with 5% CO2. After 24–72 h days post-Tet release, cells
were incubated in XTT solution for 4 h and reduction of the
tetrazolium salt was quantiﬁed with an ELISA plate reader,
as described by the manufacturer (Roche). The absorbance
directly correlates with the cell number. All experiments
were carried out in triplicate.
Flow cytometry, cell cycle analysis and TUNEL assay
For cell cycle analysis, at the indicated times, Tet released
(Tet-Off) MCF7 cells stably expressing WT or mutant
PTEN were harvested after trypsinization and pelleted by cen-
trifugation. Cells were resuspended in 500 ml of cold PBS and
ﬁxed by addition (drop-wise) to 70% ice-cold ethanol. Fixed
cells were washed with cold PBS, labeled with propidium
iodide and analyzed by ﬂow cytometry on a FACScan ﬂow
cytometer (Becton Dickinson, San Jose, CA). Cell cycle
analysis was performed with the CELL-FIT program. All
ﬂow cytometric analyses were performed in triplicate. For
the detection of apoptosis (by TUNEL), at the indicated
times, cells were harvested by centrifugation after trypsiniza-
tion, pelleted by centrifugation and washed with PBS. Cells
were ﬁxed in 1% PFA (prepared in PBS) for 15 min on ice.
Fixed cells were then washed twice with PBS, resuspended
in 500 ml cold PBS and ﬁxed in 70% ice-cold ethanol.
Samples were stored at 2208C until analysis. Flow cytometry
was performed using a Beckman-Coulter elite ﬂow cytometer
using a 610 long pass ﬁlter for data collection. Data were then
ﬁltered, after which cell phases and apoptotic cells were quan-
tiﬁed using the ModFit program (Verity Software, Bowdoin,
ME). All experiments were carried out in triplicate.
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